Press Release
March 22, 2023
In comparison to Europe and Asia, which have approximately 30 sunscreen active ingredients available for product use, the U.S. market has the fewest approved sunscreen actives. Currently, only 9 of 12 available active ingredients are commonly used for formulating marketable sunscreen products in the U.S. No new UV filters have been approved for use in the U.S. for 24 years since 1999. Skin cancer is the fastest growing cancer in the U.S. and more people will be diagnosed with skin cancer this year than all other cancers combine
Kaiseraugst (CH), 1 March 2024
In comparison to Europe and Asia, which have approximately 30 sunscreen active ingredients available for product use, the U.S. market has the fewest approved sunscreen actives. Currently, only 9 of 12 available active ingredients are commonly used for formulating marketable sunscreen products in the U.S. No new UV filters have been approved for use in the U.S. for 24 years since 1999. Skin cancer is the fastest growing cancer in the U.S. and more people will be diagnosed with skin cancer this year than all other cancers combined.
dsm-firmenich is the only company independently investing in innovation with PARSOL® Shield (Bemotrizinol) and the first company to ask the FDA and Congress to accelerate the introduction of novel UV Filter innovation to the marketplace so that Americans have more choices and access to the best technology and innovation to be Safer UNDER THE Sun, for themselves and their loved ones.
Carl D’Ruiz, Senior Business Development Manager of dsm-firmenich and Lambros Kromidas, M.S., Ph.D. VP, Global Legal – Regulatory Affairs Liaison of Shiseido Americas share the brewing sunscreen public health crisis in the U.S. with their expertise on sunscreen actives. The FDA process will ultimately determine new innovation of UV Filters on the market which will improve sun safety, skin health, and the well-being of all American diverse skin types across the country.
For more information, you can read the full published Happi article here.